ArticleCancer genomics & proteomics
Combination of Circulating Tumour DNA and
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Autophagy-Circulating Tumor DNA Axis in Molecular Cancer Research: Emerging Mechanisms, Therapeutic Targeting, and Translational Opportunities.International journal of molecular sciences · 2026Review
- Article
- Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting.Discover oncology · 2026Review
- Liquid Biopsies and Molecular Imaging for Precise Cancer Management.Methods in molecular biology (Clifton, N.J.) · 2026Review
- New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.EMBO molecular medicine · 2025Review
- Cross-Sectional Analysis of Metabolic Tumor Burden Detected by F-18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer.Cancer medicine · 2025Article
- Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary.BMJ case reports · 2025Article
- Circulating Tumor DNA and [Diagnostics (Basel, Switzerland) · 2025Article
- Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques.Cancer management and research · 2025Review
- Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes.Cancers · 2024Review
- Associations between detectable circulating tumor DNA and tumor glucose uptake measured byBMC cancer · 2023Article
- Clinical value of peripheral blood circulating tumor DNA in predicting the efficacy of immunotherapy for non-small cell lung cancer.Journal of thoracic disease · 2023Article
- The reproducibility of MTV and TLG of soft tissue tumors calculated by FDG-PET: Comparison between the lower limit by the fixed value SUV 2.5 and that value by 30% of SUVmax.Japanese journal of radiology · 2023Article
- Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment.Exploration of targeted anti-tumor therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimCirculating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of advanced-stage NSCLC patients treated with chemotherapy. PATIENTS AND
methodsEighty-four patients were enrolled in this study.
resultsThere was a correlation of ctDNA with metabolic tumour volume (MTV), total lesion glycolysis (TLG), and iodine concentration (IC) at baseline (p=0.001, p=0.001, p=0.003) and at follow-up (p=0.006, p=0.002, p=0.001). The objective response was associated with follow-up ctDNA (p<0.001) and the change of all PET/CT parameters. ROC analyses showed that the combination of follow-up ctDNA with changes in SUVmax is very promising for the estimation of objective response and progression-free survival.
conclusionThe combination of ctDNA assessment with PET/CT is a promising approach for the follow-up monitoring of therapy response and prognosis estimation of advanced-stage NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.